Troy Messick (The Wistar Institute, USA)“Development of an EBNA1 Inhibitor for the Treatment of NPC: Toward First-in-Human Studies” EBNA1 is master regulator of ENBV latency ENA1 is the only viral protein expressed in all EBV cancers EBNA1 is required for cell transformation and tumorigenesius EBNA1 structure is now and druggable No EBNA1 orthologs in human […]
Anne Lee (The University of Hong Kong, Hong Kong SAR China & The University of Hong Kong at Shunzen) “Challenges and Novel Approaches in Radiotherapy for Nasopharyngeal Carcinoma” HKNPC1301 study on IMRT (2001-2010) to further improve tomorrow control for poor risk group IMRT: parotid sparing (randomized trials on IMRT (late toxicity following IRT) Radiotherapy –
Danny Rischin (Peter MacCallum Cancer Centre, Australia)“Role of Chemotherapy in NPC: Not Novel, but Still Challenging” Discussion Leader (Brian OSuillivan): Danny Rischin is a leader of HNSCC! 哈，找了下PubMed還真的做許多HNSC相關研究 e.g. J Oral Pathol Med. 2018 Jan;47(1):18-24. The role of human papillomavirus in p16-positive oral cancers.Belobrov S1, Cornall AM2,3,4, Young RJ5, Koo K6, Angel C7, Wiesenfeld D1,6,8, Rischin
Maria Massucci (Karolinska Institutet, Sweden)“A Role of Bacterial Co-Infection in the Pathogenesis of NPC?” in immunosuppressive considerations. EBV positivity1. Immunotherapy blasting clymohoma (60&) CNS localization (100%)3. Post-transplant lymphoma (100%)4. Lymphoma of the elderly (100%)5. Leiomyosarcoma (smooth muscles)[evidence suggesting the involvement of bacterial infections in NPC pathogenesis]• NPC is often associated with chronic bacteria infections
Pierre Busson (Gustave Roussy, France)“Galectin-9 and Other Factors of Immune Escape in NPC Tumor Microenvironment: How to Bring Them Under Control?” Overview of TME [Co-evolution of tumor and stroma]M. Here’s at al, J Pathol 2013 (squamous-columnar junction cells From tumor micro environment to tumor macro-environment A gradient from tumor interstitial to the bloodstream Distant site: